Skip to main content
MJH Life Sciences
  • Login
  • Register
  • Login
  • Register
Home
  • News
  • Topics
  • Image IQs
  • Treatment Guidelines
  • Conferences
  • Slideshows
  • Contribute to Site
  • Job Board
MJH Life Sciences

SUBSCRIBE: eNewsletter

2019 ACR/ARP Annual Meeting Roundup
2019 ACR/ARP Annual Meeting Roundup

The 2019 American College of Rheumatology/Association of Rheumatology Professionals annual meeting wrapped Nov. 13 in Atlanta. On this page, we highlight key presentations made at the meeting. (©PaulRommer, AdobeStock).

ACR

Guselkumab Safe, Efficient in Biologic-Naïve Patients With Active Psoriatic Arth

Guselkumab Safe, Efficient in Biologic-Naïve Patients with Active Psoriatic Arthritis

November 12, 2019
  • Katie Robinson

ACR Annual Meeting:  In patients with active psoriatic arthritis, who are biologic-naïve, guselkumab (Tremfya, Janssen) improved joint and skin symptoms, physical function, quality of life, and resolved enthesitis and dactylitis, according to a study presented at annual meeting of the American College of Rheumatology in Atlanta on November 12.

  • READ >>
Live Varicella Vaccine Is Safe and Effective in Patients Taking TNF Inhibitors

Live Varicella Vaccine Is Safe and Effective in Patients Taking TNF Inhibitors

November 23, 2019
  • Rheumatology Network Editorial Staff

The safety of live virus vaccines in patients receiving biologic therapies was confirmed in a study of 617 patients recently presented at the American College of Rheumatology annual meeting this month.

  • READ >>
Senior Rheumatoid Arthritis Patients May Be Missing Out on Treatments

Senior Rheumatoid Arthritis Patients May Be Missing Out on Treatments

November 22, 2019
  • Rheumatology Network Editorial Staff

Even though senior patients with rheumatoid arthritis receive biologic therapies less often than patients who develop the condition early in life, a Japanese study presented this month at the ACR annual meeting, shows that patients 60 years and older can benefit from therapy just as much as younger patients.

  • READ >>
Preliminary Study Shows Promise in Immunotherapy for Rheumatoid Arthritis

Study Shows Promise in Immunotherapy for Rheumatoid Arthritis

November 22, 2019
  • Rheumatology Network Editorial Staff

Researchers are exploring the possibility of using immune checkpoint inhibitors in rheumatoid arthritis patients. A small study presented at the American College of Rheumatology (ACR) annual meeting earlier this month shows that rheumatoid arthritis (RA) patients who were treated with immunotherapy, responded just as well as a comparable patient population with only 12 of 22 patients experiencing flares.

  • READ >>
Trial Shows Switch from Etanercept Biologic to Biosimilar Maintains Clinical Out

Trial Shows Switch from Etanercept Biologic to Biosimilar Maintains Clinical Outcomes

November 21, 2019
  • Frieda Wiley, PharmD

A new study shows that the clinical status of patients who have either rheumatoid arthritis or axial spondyloarthritis, can be successfully maintained when switching from the biologic originator etanercept to a biosimilar called SB4.

  • READ >>
Methotrexate Controls Joint Damage in Hand Osteoarthritis, Small Study Shows

Methotrexate Controls Joint Damage in Hand Osteoarthritis, Small Study Shows

November 18, 2019
  • Rheumatology Network Editorial Staff

The first-ever study designed to assess the effectiveness of methotrexate on hand osteoarthritis finds that while the treatment did not demonstrate superior efficacy over placebo on pain or function, it did significantly reduce the progression of joint damage.

  • READ >>

One Step Closer for Macrophage Activation Syndrome Testing in Juvenile Arthritis

November 18, 2019
  • Rheumatology Network Editorial Staff

Researchers reporting at the annual meeting of the American College of Rheumatology earlier this month say they have successfully identified a specific biomarker for macrophage activation syndrome, a complication of childhood rheumatic disease most often affecting children with systemic juvenile idiopathic arthritis.

  • VIEW NOW >>
Ninfetanib Improves and Stabilizes Lung Function in Systemic Sclerosis

Ninfetanib Improves and Stabilizes Lung Function in Systemic Sclerosis

November 18, 2019
  • Frieda Wiley, PharmD

Patients who have systemic sclerosis-associated interstitial lung disease and received nintedanib were more likely to have improved lung function than patients who received a placebo, according to a new study. Not only did nintedanib improve forced vital capacity, but patients who received the drug were less likely to experience declining clinical status and more likely to see their conditions stabilize.

  • READ >>
New Etiology of Rheumatoid Arthritis Identfied in the Gut Microbiome

New Etiology of Rheumatoid Arthritis Identified in the Gut Microbiome

November 18, 2019
  • Frieda Wiley, PharmD

Scientists now have a better understanding of the relationship between the gut microbiome and rheumatoid arthritis.

  • READ >>

ACR Annual Meeting Roundup: Higher death rates in lupus

November 15, 2019
  • Rheumatology Network Editorial Staff

In today's slideshow, we highlight the best of the ACR Annual Meeting which wrapped this week in Atlanta. Among the highlights, includes a study that focuses on unusually high death rates in lupus, plus one that suggests new treatments for juvenile idiopathic arthritis are "urgently" needed. Learn more in this slideshow.

  • VIEW NOW >>

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • next ›
  • last »

Resource Topics rightRail

  • Resource Topics
  • Partner Content
  • Lupus
  • Rheumatoid Arthritis
  • Psoriatic Arthritis Quiz
  • Spondyloarthritis
  • Psoriatic Arthritis
JAK Inhibitors for Rheumatoid Arthritis: Historical Perspectives and Postmarketing Clinical Reports
Connect with Us
  • Column 1
    • Home
    • About Us
    • Contact Us
  • Column 2
    • Editorial Info
  • Column 3
    • Advertising Info
    • Reprints
    • Advertising Terms
  • Column 4
    • Terms of Use
    • Privacy Policy
Modern Medicine Network
© UBM 2019, All rights reserved.
Reproduction in whole or in part is prohibited.

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".